EXPRESSION OF RAT STRIATAL D1 AND D2 DOPAMINE RECEPTOR MESSENGER-RNAS - ONTOGENIC AND PHARMACOLOGICAL STUDIES

被引:0
|
作者
CREESE, I [1 ]
SIBLEY, DR [1 ]
XU, SX [1 ]
机构
[1] NINCDS,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The developmental characteristics of D1 and D2 dopamine receptor mRNA levels were determined by Northern blot analyses. Striatal D1 and D2 receptor mRNAs of male Fischer 344 rats were about 60% of adults levels at postnatal day 1 and reached their highest measured levels at day 30 (126-139% adults levels) and then decreased by day 120 (100%). D1 and D2 receptor densities at day 30 were about 8-fold higher than at day 1, while mRNA levels showed only a 2-fold increase. The highest level of D2 receptor mRNA in midbrain as reached at day 14 (195% adult level) while levels at day 1 were 31% higher than dose at day 120. Treatment with selective D2 receptor antagonist, haloperidol (0.5 mg/kg/day, s.c., for 2 h, 7,14,21 days or 21 days + 3 days withdrawal) had no effect on Sprague-Dawley rat striatal D2 receptor mRNA levels in spite of significant increases in receptor density at the later time points. However, the selective D1 receptor antagonist, SCH 23390 (0.5 mg/kg/day, s.c.) produced increases in striatal D1 receptors and mRNA levels after treatments of 7,14 and 21 days + 3 days withdrawal.
引用
收藏
页码:S45 / S48
页数:4
相关论文
共 50 条
  • [41] Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat
    Hauber, W
    Lutz, S
    BEHAVIOURAL BRAIN RESEARCH, 1999, 106 (1-2) : 143 - 150
  • [42] EFFECT OF CHRONIC NICOTINE TREATMENT AND WITHDRAWAL ON RAT STRIATAL D1 AND D2 DOPAMINE-RECEPTORS
    KIRCH, DG
    TAYLOR, TR
    CREESE, I
    XU, SX
    WYATT, RJ
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (02) : 89 - 92
  • [43] Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
    Weeks, RA
    Piccini, P
    Harding, AE
    Brooks, DJ
    ANNALS OF NEUROLOGY, 1996, 40 (01) : 49 - 54
  • [44] Genetic variants of dopamine D2 receptor impact heterodimerization with dopamine D1 receptor
    Ewa Błasiak
    Sylwia Łukasiewicz
    Kinga Szafran-Pilch
    Marta Dziedzicka-Wasylewska
    Pharmacological Reports, 2017, 69 : 235 - 241
  • [45] CLONING AND CHARACTERIZATION OF THE OPOSSUM KIDNEY-CELL D1 DOPAMINE-RECEPTOR - EXPRESSION OF IDENTICAL D1A AND D1B DOPAMINE-RECEPTOR MESSENGER-RNAS IN OPOSSUM KIDNEY AND BRAIN
    NASH, SR
    GODINOT, N
    CARON, MG
    MOLECULAR PHARMACOLOGY, 1993, 44 (05) : 918 - 925
  • [46] Evidence against dopamine D1/D2 receptor heteromers
    Frederick, A. L.
    Yano, H.
    Trifilieff, P.
    Vishwasrao, H. D.
    Biezonski, D.
    Meszaros, J.
    Urizar, E.
    Sibley, D. R.
    Kellendonk, C.
    Sonntag, K. C.
    Graham, D. L.
    Colbran, R. J.
    Stanwood, G. D.
    Javitch, J. A.
    MOLECULAR PSYCHIATRY, 2015, 20 (11) : 1373 - 1385
  • [47] Dopamine D1–D2 receptor heterodimers: A literature review
    Vekshina N.L.
    Anokhin P.K.
    Veretinskaya A.G.
    Shamakina I.Y.
    Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2017, 11 (2) : 111 - 119
  • [48] DOPAMINE RECEPTOR SUBTYPES - BEYOND THE D1/D2 CLASSIFICATION
    ANDERSEN, PH
    GINGRICH, JA
    BATES, MD
    DEARRY, A
    FALARDEAU, P
    SENOGLES, SE
    CARON, MG
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) : 231 - 236
  • [49] D1 AND D2 DOPAMINE RECEPTOR MECHANISMS IN DOPAMINERGIC BEHAVIORS
    KOLLER, WC
    HERBSTER, G
    CLINICAL NEUROPHARMACOLOGY, 1988, 11 (03) : 221 - 231
  • [50] Constitutive activity of a chimeric D2/D1 dopamine receptor
    Kozell, LB
    Neve, KA
    MOLECULAR PHARMACOLOGY, 1997, 52 (06) : 1137 - 1149